¡¾µ÷¼Á¡¿±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2024Äê16¸öרҵ½ÓÊܵ÷¼Á
²é¿´: 786  |  »Ø¸´: 1

zhounailu

½û³æ (³õÈëÎÄ̳)


[×ÊÔ´] ¡¾¿´Íê²»ºó»ÚϵÁС¿Ò½Ñ§ÂÛÎÄд×÷¹¥ÂÔ£¡£¡£¡

ҽѧÂÛÎÄ(medical papers)ÊÇÕûÀíºÍ·¢±íҽѧÑо¿³É¹ûµÄÒ»ÖÖÌØÊâÎı¾µÄ×ܳƣ¬¾ÍÆäÄÚÈݺÍÎÄÌåÌصã¶øÑÔ¿É·ÖΪÒÔϼ¸ÖÖ£ºÒ½Ñ§¿ÆÑÐÂÛÎÄ(scientific papers)£»µ÷²é±¨¸æ(survey)£»×ÛÊö(review)£»Ñ§Î»ÂÛÎÄ(theses)¡£             £¨ÎÄÄ©ÓÐÈ«Ì×д×÷ѧϰÊÓƵ£©


       ¹ú¼ÊÉúÎïѧ±à¼­Î¯Ô±»á¶Ôҽѧ¿ÆÑÐÂÛÎĵĶ¨ÒåΪ£º±ØÐëÊÇÊ״ι«²¼µÄÓ¦Ìṩ×ã¹»µÄ×ÊÁÏ£¬Ê¹Í¬ÐÐÃÇÄܹ»½øÐУº¢ÙÆÀ¼ÛËù¹Û²ìµ½µÄ½á¹û£»¢ÚÆÀ¼ÛÆäÍÆÀí¹ý³Ì£»¢ÛÖظ´ÊµÑé¡£·ÖΪÒÔÏÂ2ÖÖ£ºÁÙ´²Ñо¿(clinical study)£»»ù´¡Ñо¿»òʵÑéÑо¿(experimental study)¡£

      ÔÚ¸ßУҽѧԺºÍҽѧ¿ÆÑлú¹¹µÄѧÊõÑо¿ºÍ¶ÔÍâ½»Á÷ÖУ¬Ò½Ñ§·­ÒëºÍд×÷ÊDZز»¿ÉÉÙµÄÒ»¸ö»·½Ú£¬¶øÓïÑÔ·­Ò빤×÷ÕßÒ²¾­³£»áÅöµ½ÂÛÎÄ·­ÒëµÄÐèÇó£¬ÔÚÕâ¸öÂÛÎÄ·­ÒëµÄÍú¼¾£¬Ò½Ñ§ÂÛÎÄ·­ÒëÎÞÒÉÊÇ´óÍ·¡£

      ÄÇôҪ½øÐÐҽѧ·­Ò룬¾Í±ØÐë¶ÔҽѧÂÛÎĵĿò¼ÜÓÐÒ»¶¨µÄÁ˽⡣ÏÂÃæ½éÉÜÁ½¸öÓ¢ÎÄÂÛÎĵĿò¼Ü¡£

Ò»¡¢Ò½Ñ§¿ÆÑÐÂÛÎĵĸñʽ×ۺϰæ
¸ù¾ÝҽѧÔÓÖ¾±à¼­¹ú¼ÊίԱ»áÖƶ¨µÄ¡¶ÉúÎïҽѧÔÓ־Ͷ¸åͳһҪÇó¡·Ò»ÆªÉúÎïҽѧ¿ÆÑÐÂÛÎÄ£¨ÒÔϼò³Æ¡°ÂÛÎÄ¡±£©Ó¦°üÀ¨ÒÔÏÂ12¸ö²¿·Ö£º
1.±êÌâ(Title)
2.ÕªÒª(Abstract)
3.ÒýÑÔ(Introduction)
4.²ÄÁÏÓë·½·¨(Materials and Methods)
5.½á¹û(Results)
6.ÌÖÂÛ(Discussion)
7.ÖÂл(Acknowledgements)
8.²Î¿¼ÎÄÏ×(References)
9.²åͼ˵Ã÷(Legends)
10.²åͼ(Figures)
11.±í¸ñ(Tables)
12.ÕÕƬºÍ˵Ã÷(Plates and Explanations)
ÒÔÉϳý7¡¢9¡¢10¡¢11¡¢12²¿·ÖÒòʵ¼ÊÇé¿ö²»ÐèÒªÍ⣬ÆäËû¸÷²¿·ÖÊÇһƪÂÛÎıز»¿ÉÉÙµÄÄÚÈÝ¡£

1¡¢ÒýÑÔ²¿·Ö
×ܵÄÒªÇó£º
˵Ã÷Ñо¿µÄ×ÜÌ巶ΧºÍÄ¿µÄ¡£
¾ßÌåÒªÇó£º
A. ±³¾°¨C˵Ã÷ËùÑо¿ÎÊÌâµÄÄ¿Ç°×ÜÌåÇé¿ö»òÀúÊ·(statement of general area or history ofproblem)£»
B. ÒâÒå¨C˵Ã÷Ñо¿µÄÒâÒå»ò±ØÒªÐÔ(statement of importance or need)£»
C.½øÕ¹¨C˵Ã÷ÓйظÃÎÊÌâµÄÏÈÓз¢ÏÖ¡¢±¨¸æ»òÑо¿(statement of previous findings,reports orstudies)¡£³ÂÊöÕⲿ·ÖÄÚÈÝʱһ°ãÒªÓÐÒýÎÄ(citations)£»
D. Ä¿µÄ¨C˵Ã÷±¾Ñо¿µÄÄ¿µÄ(statement of purpose of current study)£»
E. ·¶Î§¨C˵Ã÷ÒªÑо¿ÎÊÌâµÄ¾ßÌ巶Χ(statement of specific area of problem to bestudied)

2¡¢²ÄÁÏÓë·½·¨²¿·Ö
×ܵÄÒªÇó£º
½á¹ûµÄ¿ÉÖØÑÝÐÔ¡¢·½·¨µÄ¿É*ÐÔÒÔ¼°Ç°ºóµÄÂß¼­ÐÔ¡£
¾ßÌåÒªÇó£º
A. ¼òҪ˵Ã÷Ñо¿Éè¼Æ(study design/protocol)£¬È磺»Ø¹Ë(retrospective/review)£¬Ç°Õ°(prospective)£¬ÁÙ´²(clinical)£¬¶¯Îï(animal)£¬ÊµÑé(experimental)£¬»îÌåÄÚ(in vivo) »îÌåÍâ(in vitro)£¬Ô­Î»(in situ) Ëæ·Ã(follow-up)£¬¶ÔÕÕ(controlled)£¬Ëæ»ú(random/randomized)£¬Ë«Ã¤½»*(double- blind crossover)£¬ÈËȺ(population/cohort/migrant)£¬¶Ô±È(comparative)£¬Á÷Ðв¡Ñ§(epidemiological) µÈÑо¿ÐÔÖÊ£»
B. Ïêϸ˵Ã÷Ñо¿¶ÔÏó(subject) Çé¿ö£¬°üÀ¨Ñо¿ÈËÔ±(student)£¬±»Ñо¿µÄÈË(client) ºÍ¶¯Îï(animal) µÄÐÔ±ð(***)¡¢ÄêÁä(age)£¬ÎïÖÖ(species)£¬Æ·ÖÖ(breed) ÉúÀí״̬(physiological state)£»Î¢ÉúÎïÔòҪ˵Ã÷Æä¾úÖê(strain)£¬ÑªÇåÐÍ(serotype) ¼°ÆäËûÇø±ðÌØÐÔ(identity characteristics)£»
C. Ëæ»ú·Ö×é·Ö×é·½·¨(methods of any random assignment of subjects togroups) ºÍÑ¡Ôñ±ê×¼(criteria for admission to study groups)£»
D. Ïêϸ˵Ã÷ËùÓõÄÒ©Îï(drug)£¬¼¤ËØ(hormone)£¬ÊÔ¼Á(reagent) ºÍÆäËû»¯Ñ§Æ·(chemical) µÄÃû³Æ¡¢É̱ê(trademark)¡¢Éú²ú³§¼Ò(manufacturer)¼°ËùÔÚµØ(location)
E. ¼òҪ˵Ã÷²â¶¨·½·¨(method of measurement)£¬°üÀ¨Ãû³Æ£¬ÒýÎĺÍÆ«²î(variations);
F. ¼òҪ˵Ã÷ͳ¼Æѧ·ÖÎö·½·¨(method of statistic analysis)
Õⲿ·ÖµÄ³ÂÊö³ÌÐòÒ»°ãΪ£ºÑо¿Éè¼Æ¡úÑо¿¶ÔÏóÐÔÖÊ¡ú´¦Àí/¸ÉÔ¤·½·¨¡ú²â¶¨/¹Û²ìÊֶΡúͳ¼Æ·ÖÎö¡£
³ýָʾÐÔ˵Ã÷Í⣬È磺¡°²¡ÈË×ÊÁϼû±í1¡±(Data of the patients are shown in Table 1) ¡°²ÄÁÏÓë·½·¨¡±ºÍ¡°½á¹û¡±Á½²¿·ÖÒ»ÂÉÓùýȥʱ±í´ï¡£

3¡¢½á¹û²¿·Ö
×ܵÄÒªÇó£º
ÈÃÑо¿µÄ¿Í¹Û½á¹û˵»°£¬²»ÒªÌíÖ¦¼ÓÒ¶¡£
¾ßÌåÒªÇó£º
A. ¶ÔËù»ñ½á¹û½øÐиÅÊö(overview of the results);
B. ˵Ã÷Ëù»ñ×ÊÁÏ»òÊý¾ÝµÄͳ¼ÆÒâÒå(statistical significance);
ͳ¼ÆÖ§³Ö(statisticalsupport)£¬°üÀ¨Í¼£¬±í£¬ÕÕƬµÈ(·²ÓÃͼ±í±íʾµÄÄÚÈݲ»ÔÙÓÃÎÄ×ÖÏêÊö)¡£²»ÒªÓÃÄ£ÀâÁ½¿ÉµÄ´Ê»ò¶ÌÓï±íÊö½á¹û£¬È磺¡°Theresults tended to be greater than¡­¡±¡£

4¡¢ÌÖÂÛ²¿·Ö
×ܵÄÒªÇó£º
ÓëÏÈÓÐÑо¿Ïà±È£¬±¾Ñо¿ÓкÎÒâÒå¡£
¾ßÌåÒªÇó£º
A. ¼òҪ˵Ã÷Ñо¿±³¾°(background)
B. ¼òÒª½éÉÜ×ܵķ¢ÏÖ(general findings);
C. ½éÉܾßÌåÒªµã(introduction of points)
D. ÓëÏÖÓз¢ÏÖ(ÈôÓÐ)½øÐбȽÏ(comparison in the context of other studies)
E. ÒâÒå(suggested meaning)
F. ½áÂÛ(conclusion)
G. Ç°Õ°Ñо¿(future studies)
½áÂÛÍùÍùÊÇÂÛÎÄÖÐ×ҲÊÇ×îÄÑдµÄ²¿·Ö£¬Ö÷ÒªÔ­ÒòÊÇ×÷ÕßÒª¶ÔÑо¿½á¹ûºÍ·¢ÏÖ½øÐзÖÎö¡¢Íƶϡ¢ÑÝÒïºÍÍÆÀí£¬ÒªÇó×÷Õß¾ßÓкÜÇ¿Âß¼­Ë¼Î¬ÄÜÁ¦ºÍÓ¢ÓïÎÄ×Ö×éÖ¯ÄÜÁ¦¡£´ËÍ⣬Õⲿ·Öʱ̬±È½Ï¸´ÔÓ£¬Òª·ÖÇåʵÑé¹ý³ÌºÍ½á¹û(¹ýȥʱ)Óë·ÖÎöÒâ¼û(È·¶¨£ºÏÖÔÚʱ;²»È·¶¨»ò¼ÙÉ裺¹ýȥʱ)µÄÇø±ð;ËûÈËÑо¿½á¹û(¹ýȥʱ»òÏÖÔÚÍê³Éʱ)Óë±¾Ñо¿½á¹û(¹ýȥʱ)µÄÇø±ð;ÆÕ±éÊÊÓõĽáÂÛ(ÏÖÔÚʱ)ÓëÖ»ÊÊÓñ¾Ñо¿µÄ½áÂÛ(¹ýȥʱ)µÄÆä±ðµÈ¡£Òò´Ë£¬¶ÔÓÚhowever, may, might, could, would, possibly,probably, be likely to µÈ´Ê(×é)µÄʹÓÃÒÔ¼°we believe (think/consider) that, to ourknowledge, in our experience (practice) µÈ²åÈëÓïµÄʹÓþÍÏԵøñÍâÖØÒª¡£

5¡¢ÖÂл²¿·Ö
×ܵÄÒªÇó£º
ÖÂл´ÊºÍÖÂл·½Ê½±ØÐëÕ÷µÃÊÜлÈË»òµ¥Î»µÄͬÒâ¡£

6¡¢²Î¿¼ÎÄÏ×
×ܵÄÒªÇó£º
Referencestyles should be specific to eachjournal,¼È£º¸ù¾Ý¸÷ÔÓÖ¾µÄ¾ßÌåÒªÇó£¬ÒòΪ¸÷ÔÓÖ¾¶Ô²Î¿¼ÎÄÏײ¿·ÖµÄ±àÅÅ˳ÐòºÍ¸ñʽ²»¾¡Í³Ò»¡£
ÏÖ½«URMSBJÒªÇóµÄ20¶àÖֲο¼ÎÄÏ×ÖÐ×î³£¼ûµÄ5ÖÖ¸ñʽÁоÙÈçÏ£º
1) Vega KJ,Pina I,Krevsky B.Heart transplantation is associated with anincreased risk for pancreatobiliary disease.Ann Intern Med 1996 Jun1;124(11):980-3. [±ê×¼ÔÓÖ¾ÎÄÕÂ]
2) The Cardiac Society of Australia and New Zealand.Clinical excisestress testing:Safety and performance guidelines.Med J Aust1996;164:282-4. [×÷ÕßÊǸö×éÖ¯]
3) Cancer in South Africa[editorial].S Afr Med J 1984;84:15. [ÎÞ×÷ÕßÃû]
4) Shen HM,Zhang QF.Risk assessment of nickel cardiogenicity andoccupational lung cancer.Environ Health Perspect 1994;102 Suppl1:275-82.[ijÔÓÖ¾Ôö¿¯]
5) Browell DA,Lennard TW.Immunologic status of the cancer patient andthe effects of blood transfusion on antitumor responses.Curr Opin GenSurg 1993;325-33 [ÎÞÆÚÎÞ¾í]

7¡¢²åͼ˵Ã÷
×ܵÄÒªÇó£º
²åͼ˵Ã÷ÒªÁíҳ˫ÐдòÓ¡¡£µ±²åͼÖÐÓмýÍ·(arrow)¡¢·ûºÅ(symbol)¡¢Êý×Ö(number)»ò×Öĸ(letter)ʱ£¬ÒªÔÚÕⲿ·Ö(²»ÊÇÔÚ²åͼҳÉÏ)¶ÔÆä·½Ïò¡¢Î»ÖõÈ×÷³ö·Ç³£Ã÷È·µÄ˵Ã÷¡£

8¡¢²åͼ
×ܵÄÒªÇó£º
Designyour figures for the appropriatereduction,¼´£º²åͼҪ°´ÔÓÖ¾µÄ°æÃæ´óС±ÈÀý½øÐÐѹËõ;²»Òª°Ñ²åͼÅijÉÕÕƬ¡£

9¡¢±í¸ñ
×ܵÄÒªÇó£º
Atable should be a totally self-contained unit ofinformation,¼´£º±í¸ñÒª×÷Ϊһ¸ö¶ÀÁ¢µÄÐÅÏ¢µ¥Î»ÁíÒ³´òÓ¡¡£±í¸ñÒª¼òÃ÷Çå³þ£¬ÍêÕû(±êÌâ¡¢ÄÚÈݺͽÅ×¢)£¬¼´Ê¹Ö»ÓÐÒ»Õűí¸ñÒ²Òª±êTable1¡£

¶þ¡¢Ò½Ñ§¿ÆÑÐÂÛÎĵĸñʽ¼òÃ÷°æ
1¡¢±êÌ⣨title£©
2¡¢ÕªÒª£¨abstract£©
3¡¢ÒýÑÔ£¨introduction£©
4¡¢²ÄÁϺͷ½·¨£¨materialsand methods£©
5¡¢½á¹û£¨results£©
6¡¢ÌÖÂÛ£¨discussion£©
7¡¢ÖÂл£¨acknowledgement£©
8¡¢²Î¿¼ÎÄÏ×£¨references£©

1¡¢±êÌâ
1£©ÒªÇó
¼òÃ÷¶óÒª£¨shortand concise£©£º¾¡Á¿¿ØÖÆÔÚÒ»ÐУ¬µ«²»ÊÇÒ»¸ö¾ä×Ó£»²»³¬¹ý25¸öµ¥´Ê»ò120-140¸ö×Öĸ£»³ýDNA¡¢RNA¡¢CTµÈ²»ÓÃËõд¡£
A. ÐÅÏ¢·á¸»£¨informative£©
B. ±ãÓÚË÷Òý£¨indexing£©
C. ½Ï³¤±êÌâ¿É²ÉÓø±±êÌâ

2£©±êÌâд×÷Öг£ÓôÊ×éºÍ±í´ï·½Ê½
Óá­£¨·½·¨£¯ÊֶΣ©¶Ô¡­½øÐÐÑо¿£¯·ÖÎö£¯¹Û²ì£¯ÆÀ¼Û£º
Study(analysis/observation/evaluation/assessment)of (on) ¡­  by (using ·½·¨/with¹¤¾ß)

A¶ÔBµÄ×÷ÓÃ
EffortofA on B
Protective effect of omeprazole onendothelin-induced gastric mucosal injury

AÓëBµÄ¹Øϵ
Correlation(relation/relationship)between A and B
Correlationof A with B and C

³£ÓÃÐÞÊδÊ
positively/negatively/significantly/insignificantly

Óá­ÖÎÁÆ¡­
Useof ¡­in the treatment of ¡­(²¡£©in¡­£¨ÉúÎ
Useof omeprazole in the treatment of gastric ulcer in the elderly

AÊÇB
A as B

2¡¢ÕªÒª
1£©ÕªÒª·ÖÀà
ÕªÒªÊÇ×÷ÕßÒª¸ø¶ÁÕߵľ«»ª£¬´ÓÄÚÈÝÉÏ·ÖÁ½´óÀࣺ
A. ָʾÐÔÕªÒª
B. ×ÊÁÏÐÔÕªÒª
´Ó½á¹¹·ÖΪÈý´óÀࣺ
A. ·Ç½á¹¹Ê½ÕªÒª
B. È«½á¹¹Ê½ÕªÒª
C. °ë½á¹¹Ê½ÕªÒª

2£©·Ç½á¹¹Ê½ÕªÒª
ȱµã£º¶ÎÂä²»Ã÷£¬¸ø±à¼­¡¢Éó¸å¡¢ÔĶÁºÍ¼ÆËã»ú´¦Àí´øÀ´Öî¶à²»±ã

3£©È«½á¹¹Ê½ÕªÒª
°ËÒªËØÕªÒª£ºÄ¿µÄ£¬Éè¼Æ£¬µØµã£¬¶ÔÏ󣬴¦Àí£¬Ö÷Òª²â¶¨ÏîÄ¿£¬½á¹û£¬½áÂÛ¡£
Óŵ㣺¹Ûµã¸üÃ÷È·£¬ÐÅÏ¢Á¿¸ü´ó£»²î´í¸üÉÙ£»·ûºÏ¼ÆËã»úÊý¾Ý¿â½¨Á¢ºÍʹÓÃÒªÇó¡£
ȱµã£º·³Ëö¡¢Öظ´¡¢Æª·ù¹ý³¤

4£©°ë½á¹¹Ê½ÕªÒª
¼´ÎªËÄÒªËØÕªÒª£º
Ä¿µÄ£¨objective/purpose/aim£©
·½·¨£¨methods£©
½á¹û£¨results£©
½áÂÛ£¨conclusion£©

3¡¢Ä¿µÄ
Ä¿µÄÊÇ×÷ÕßÏëÒª½éÉܵĹؼüÎÊÌâ¡£
1£©Ä¿µÄ¸ñʽ
µ¥±íÄ¿µÄ
±³¾°£«Ä¿µÄ

2£©Ä¿µÄ³£ÓÃʱ̬
±³¾°£ºÏÖÔÚʱ£¨Ò»°ãÏÖÔÚʱ¡¢Íê³ÉʱºÍ½øÐÐʱ£©
Ä¿µÄ£ºÒ»°ãÏÖÔÚʱ£¯ÏÖÔÚÍê³Éʱ£¬»òÒ»°ã¹ýȥʱ
¾ÙÀý1£º
Toevaluate the effects on 24-hour intragastric pH levels of infusionswithomeprazole and H2 receptor antagonists in bleeding duodenal ulcerpatients.
¾ÙÀý2£º
Therole of omeprazole in triple therapy and the impact of Helicobacterpyloriresistance on treatment outcome are not established. This studyinvestigatedthe role of omeprazole and influence of primary H. pyloriresistance oneradication and development of secondary resistance.

3£©½éÉÜÄ¿µÄ³£ÓþäÐÍ
Ö÷ÒªÓö¯´Ê²»¶¨Ê½to±í´ï
Ö±½ÓÓá°todo¶ÌÓ±í´ï
¾ÙÀý1£º
Todetermine if use of omeprazole protects against the gastric mucosalinjury
Thepurpose/aim/objective/goal (of present study is) was to
¾ÙÀý2£º
Theaim ofthis study was to determine the protective function ofomeprazole on gastricmucosal injury.
Thepresent study is /was designed/devised/intended to
¾ÙÀý3£º
Thepresent study was designed to establish whether there might be agenetic pred is position to an altered pattern of anti-inflammatorycytokine produced inpatients with irritable bowel syndrome.
Thisstudy was performed/conducted/carried out/under taken to
¾ÙÀý4£º
Anexperimental study was conducted using a canine mode to elucidate ¡­
Weaimed/sought to/attempted to
¾ÙÀý5£º
Wesought to assess whether there is an increased risk of tuberculosisamong individuals who work in certain industries occupations.

4£©½éÉÜÄ¿µÄ³£Óö¯´Ê
Ñо¿£ºstudy,investigate,examine, observe, explore
¾ÙÀý£º
Ourobjective in this report is to examine the clinical feature,pathology and treatment for patients with pancreatic cancer.
ÆÀ¼Û£ºevaluate,validate
¾ÙÀý£º
Toevaluate sonography as a tool for initial diagnosis in emergency roompatientswith abdominal trauma.
È·¶¨£ºdetermine,decide,confirm, support, define, characterize
֤ʵ£ºprove,demonstrate,document, test, support, testify, verify
²ûÃ÷¡¢¸ãÇ壺explain,elucidate,clarify, illustrate, delineate, find out, contribute to theknowledgeof
½éÉÜ£ºdescribe,present,report
½¨Á¢£ºestablish,develop,set out
Ñ°ÕÒ£ºsearchfor,look for, seek, find
ʶ±ð¡¢Çø·Ö£ºidentify,differentiate,discriminate
ÓÅÑ¡£ºoptimize
±È½Ï£ºcompare
»Ø¹Ë£ºreview
Ïà¹Ø£ºcorrelateAwith B

4¡¢·½·¨²¿·Ö
Ñо¿Éè¼Æ£»
Ñо¿¶ÔÏóµÄÌØÐÔ£»
¸ÉÔ¤»ò´¦Àí·½·¨£»
²â¶¨»ò¹Û²ì·½·¨¡£

1£©Ñо¿¶ÔÏóµÄÑ¡Ôñ¡¢À´Ô´¼°±ê×¼
ÄÉÈëÑо¿£ºwereentered into/enrolled in/selected (randomly)
¾ÙÀý£ºAtotal of 169 patients were included in the study, 83 of whomreceived¡­¡­
Åųý»òÍ˳öÑо¿£ºwereexcluded from participation£¬withdrew from the study due to/because to
¾ÙÀý£º¡­¡­Patientswith significant aortic valvular diseases were excluded.

2£©Ñо¿¶ÔÏóµÄ·Ö×é
¡­¡­were divided into/classified/grouped into
¡­¡­weredivided randomly/randomized into
¡­¡­weredivided equally into
¾ÙÀý£ºPatientswere divided into three groups: Group 1¡­¡­ Patients (n = 539) witha history of duodenal ulcer and a positive H. pylori screening testresult were randomized into 4 groups. OAC group received 20 mgomeprazole, ¡­¡­

3£©ÄêÁä
ijһÄêÁä
¾ÙÀý£ºA50-year-old patient. Patients (age 26¡À3 years).
ÔÚijÄêÁ䷶ΧÄÚ¼°Æ½¾ùÄêÁä
¾ÙÀý£ºPatientsrange in age from ¡­to¡­, with a mean of (50 years).
ÔÚijһÄêÁäÒÔÉÏ»òÒÔÏÂ
¾ÙÀý£ºPatientsmore than 50 years. Patients under/less than 50 years.

4£©ÐÔ±ð¡¢Ê±¼ä
ÐÔ±ð
twelve patients (7 male and 5 female )
The male-to-female ratio was 1:4
ʱ¼ä
Body weight was measured weekly, and liver biopsy was obtained at 4,8 and 12 weeks.¡­¡­

5£©Õï¶ÏÓëÖÎÁÆ
Õï¶Ï
be diagnosed as having ¡­
be diagnosed as ¡­by ¡­/with ¡­
besuspected as ¡­
ÖÎÁÆ
be treated with¡­(alone or in combination with ¡­)
be treated on outpatient/inpatient basis
¾ÙÀý£ºPatients(n= 539) with a history of duodenal ulcer and a positive H. pyloriscreening test result were randomized into 4 groups. OAC groupreceived 20 mg omeprazole, ¡­
¾ÙÀý£º50patients with active bleeding duodenal ulcer were randomly assignedto receiveone of the four treatment regimens. ¡­

5¡¢½á¹û²¿·Ö
ÊÇÎÄÕ½áÂ۵ĸù¾Ý£¬Ó¦¼Ç¼ÕæʵµÄ¿ÆÑÐÊý¾Ý£¬³ýָʾÐÔ˵Ã÷Í⣬һ°ãÓùýȥʱ±íʾ¡£

³£ÓþäÐÍ
½á¹û±íÃ÷
Theresults showed / demonstrated / revealed /documented /indicated/suggested¡­that¡­£»
Itwas found that¡­

¾ÙÀý£ºTheresults showed that high thigh cuff Doppler technique was 79 percentsensitive, 56 percent specific and 63 percent accurate.
Óë¡­ÓйØ
Awas related / correlated /associated with B. There was a relationship/correlation between A and B. There was a relation of A with B and C

¾ÙÀý£ºInsulin sensitivity index was negatively with blood velocity (r=0.530,P<0.05), bodymass index (r=o.563, P<0.01) and baselineinsulinemia (r=0.489, P<0.05)
Ôö¼Ó»ò¼õÉÙ
±íʾÊýÖµÔö¼ÓµÄ¶¯´Ê£ºincrease,rise,elevate
±íʾÊýÖµÔö¼ÓµÄÃû´Ê£ºincrease,increment,elevation
±íʾÊýÖµ¼õÉٵĶ¯´Ê£ºdecrease,reduce,fall, drop, decline, lower
±íʾÊýÖµ¼õÉÙµÄÃû´Ê£ºdecrease,decrement,reduction, fall, drop, decline, lowering
´Ó¡­Ôö¼Óµ½¡­£¬Æ½¾ùÔö¼Ó¡­£ºincreasefrom¡­to ¡­, with a mean/average (increase) of ¡­
´Ó¡­Ôö¼Óµ½¡­£¬×ܵÄÔö¼Ó¡­£ºincreasefrom¡­to ¡­, with an overall increase of ¡­
Ôö¼ÓÁË10£¥£ºincreaseby(10%)
±¶Êý±È½Ï
Ôö¼Ó»ò¼õÉÙ3±¶£ºincreaseby3 fold (times); a 3-fold increase
AÊÇBµÄ3±¶£ºAis 3 fold (times) as¡­as B. A is 3 fold (times) B
½á¹ûµÄͳ¼ÆѧÒâÒå
Ã÷ÏÔ²»Í¬£¨significantdifference£©
ºÜÃ÷ÏÔ²»Í¬£¨very/highlysignificant difference£©
Çø±ð²»Ã÷ÏÔ£¨insignificantdifference£©
ÎÞÇø±ð£¨nonsignificantdifference/no difference£©
ͳ¼ÆѧÒâÒå³£ÓþäÐÍ
Therewas/is significant difference in¡­between A and B
Thedifference in ¡­between A and B was/is significant
Awas/is significant difference from B in ¡­
Nosignificant difference was found / observed / noted in ¡­between Aand B
¡°in¡±±íʾÇø·ÖµÄÐÔÖÊ»òÄÚÈÝ
¾ÙÀý1£ºTherewere no significant difference between treatment groups in symptoms  andlung function (P>0.05).
¾ÙÀý2£ºSignificantdifference were not noted in the level of HDL cholesterol, and LDLpeakparticle diameter before and after treatment.

6¡¢½áÂÛ²¿·Ö
ÊÇ×÷Õß·¢±í¹ÛµãºÍ¼û½â£¬¸ø¶ÁÕߵľ«Ë貿·Ö¹éÄÉÐÔ˵Ã÷Ñо¿½á¹û»ò·¢ÏÖ½áÂÛÐÔ˵Ã÷½á¹ûµÄ¿ÉÄÜÔ­Òò¡¢»úÀí»òÒâÒåÇ°Õ°ÐÔ˵Ã÷δ½â¾öµÄÎÊÌâ¡£

1£©½áÂÛ²¿·Öʱ̬
¹ýȥʱ
a. Éæ¼°±¾Ñо¿µÄÄÚÈÝ
b. Éæ¼°ËûÈËÑо¿¹ý³ÌµÄÄÚÈÝ
c. ×÷ÕßÈÏΪֻÊÊÓÃÓÚ±¾Ñо¿»·¾³ºÍÌõ¼þµÄ½áÂÛ
ÏÖÔÚʱ
a. ָʾÐÔ˵Ã÷
b. ÆÕ±é½ÓÊܵÄ˼Ïë¡¢ÀíÂÛ»ò½áÂÛ
c. ×÷ÕßÈÏΪ±¾Ñо¿½áÂÛ¾ßÓÐÆÕ±éÒâÒå
d. Ç°Õ°ÐÔ˵Ã÷
¾ÙÀý£ºOurfindings indicate that hepatitis C is a progressive disease[ָʾÐÔ˵Ã÷-ÏÖÔÚʱ]£¬butonlya few died during the average 20.4 years after the initiation ofinjectiondrug use [±¾ÊÔÑé¹ý³ÌÖз¢ÉúµÄÊÂ-¹ýȥʱ£Ý.Antiviraltreatment to eradicate the virus and halt the progression ofdiseasesis indicated in this group of patients [×÷ÕßÈÏΪ¾ßÓÐÆÕ±éÒâÒåµÄ½áÂÛ-ÏÖÔÚʱ].

2£©½áÂÛ²¿·Ö³£ÓþäÐÍ
½á¹ûÌáʾ¡­
Theseresults suggest that¡­
¾ÙÀý£ºThesedata confirm the presence of at least two major HCV genotypes inNigeria.
½á¹ûÖ§³Ö»ò·´¶ÔijÖÖ¹Ûµã
Theseresults support the idea that¡­
Theseresults fail to support the idea that¡­
¾ÙÀý£ºTheseresults do not support the idea that treatment to lower cholesterolconcentration cause mood disturbance.
±íʾ¹ÛµãµÄÈ·¶¨»ò²»È·¶¨ÐÔ
Thereis no evidence that¡­
Itis likely/unlikely that ¡­
¾ÙÀý£ºThereis no evidence that NIDDM produce any change in bone metabolism ormass.
¾ßÓС­ÒâÒå
Beof great (some/little/no) clinical significance in¡­to ¡­
¾ÙÀý£ºThedetection of p53 gene is of great clinical significance in tumordiagnosis.
Ç°Õ°ÐÔ˵Ã÷
¡­remaintobe further studied£»
Itis remains to be proved that ¡­
¾ÙÀý£ºHowever,the relation of insulin resistance to hypertension remains to befurtherstudied.
²åÈëÓï
Thisis the first case of pancreas divisum.
¾ÙÀý£ºThisis the first case, to our knowledge, of pancreas divisum.
»Ø¸´´ËÂ¥

» ±¾Ìû¸½¼þ×ÊÔ´Áбí

  • »¶Ó­¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
    ±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æȨÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺libolin3@tal.com
  • ¸½¼þ 1 : ÉúÎïҽѧÂÛÎÄд×÷¹¥ÂÔ.docx
  • 2019-05-22 14:46:35, 104.29 K

» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍƼö: (ÎÒÒ²ÒªÔÚÕâÀïÍƹã)

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
Ïà¹Ø°æ¿éÌøת ÎÒÒª¶©ÔÄÂ¥Ö÷ zhounailu µÄÖ÷Ìâ¸üÐÂ
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍƼö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[ÂÛÎÄͶ¸å] Ò»ÉóÒ»¸öÉó¸åÈË£¬Ð¡ÐÞ£¬»áÔõôÑùѽ£¿ +4 ÁÖʦÃà 2024-04-18 4/200 2024-04-19 00:39 by ÉñÓòÒ¯
[¿¼ÑÐ] 298Çóµ÷¼Á +7 Ëï´ó´ó@ 2024-04-17 7/350 2024-04-18 19:43 by lature00
[²©ºóÖ®¼Ò] ²©ºó»»·½Ïò¿ÉÐÐÂ𣿠+3 Ô½Ô½²»±©Ôê 2024-04-15 3/150 2024-04-18 10:58 by ciompman
[ÕÒ¹¤×÷] ¼ÒÏç¶þ±¾¸ßУ/Ñغ£´«Í³Ë½Æó£¬ÈçºÎ¾ñÔñ£¿ 10+4 »¯Ñ§Ïï 2024-04-15 12/600 2024-04-18 10:51 by sayuri0712
[»ù½ðÉêÇë] ÉêÇëÊ¡×ÔÈ»¿Æѧ»ù½ð£¬Ñо¿ÇøÄÜ·ñÊÇÊ¡ÍâÇøÓò 100+3 ϲ»¶ÍÃÍõÄÎÒ 2024-04-15 11/550 2024-04-17 23:49 by ϲ»¶ÍÃÍõÄÎÒ
[¹«Åɳö¹ú] CSCÔÚÖ°ÉêÇëÇóÎÊ +5 Amber0919 2024-04-16 5/250 2024-04-17 16:15 by liaojiayan
[¿¼ÑÐ] 322Çóµ÷¼Á +7 ±¾¼ºÉÏ°¶ 2024-04-16 7/350 2024-04-17 11:49 by duanxz
[¿¼ÑÐ] Çóµ÷¼Á +4 ¹ÃÈÔÂyy 2024-04-15 5/250 2024-04-16 16:16 by chenweiwade
[¿¼ÑÐ] 296Çóµ÷¼Á +3 Cclocomotive 2024-04-16 4/200 2024-04-16 10:04 by 19862091
[²ÄÁÏ×ÛºÏ] ÇëÎÊÄÄÀï¿ÉÒÔ²âÊÔµÍѹÎüÇâµÄPCTÇúÏß +3 yunshengcd 2024-04-14 5/250 2024-04-15 13:59 by zqdsb
[¿¼ÑÐ] 274Çóµ÷¼Á +5 Ëĸö´ó×Ö£¬ÄãµÎº 2024-04-13 6/300 2024-04-15 00:01 by Ëĸö´ó×Ö£¬ÄãµÎº
[¿¼ÑÐ] Ò»Ö¾Ô¸ÏÃÃÅ´óѧ329·Ö²ÄÁϹ¤³Ìר˶Çóµ÷¼Á +10 Kaylawander 2024-04-13 11/550 2024-04-14 22:39 by liu823948201
[¿¼ÑÐ] 290Çóµ÷¼Á +3 Ñîyhr 2024-04-14 5/250 2024-04-14 21:50 by coco1981
[¿¼ÑÐ] 290£¬Ò»Ö¾Ô¸±¨¿¼ÖØÇì´óѧÉúÎïÓëҽҩר˶£¬Çóµ÷¼Á +4 GPX4 2024-04-13 5/250 2024-04-13 17:19 by lincunhui
[¿¼ÑÐ] 339Çóµ÷¼Á +9 ²ÄÁϵ÷¼Á111 2024-04-12 10/500 2024-04-13 17:07 by lincunhui
[ÂÛÎÄͶ¸å] material research express»¹Ã»½»¿ªÔ´°æÃæ·Ñ£¬ÒѾ­ÏßÉϳö°æÁË 10+3 lzjslyz 2024-04-12 3/150 2024-04-13 11:09 by kingzgh
[¿¼²©] ÏÖÔÚÉ격ºÜÍíÁËÂð +3 Îõ·çĽº® 2024-04-13 3/150 2024-04-13 11:08 by Nanamiwww
[¿¼ÑÐ] 327Çóµ÷¼Á +8 24½ì»¯Ñ§¿¼Ñе÷¼ 2024-04-12 11/550 2024-04-13 09:36 by lincunhui
[¿¼ÑÐ] 335Çóµ÷¼Á +7 Wzp123456. 2024-04-12 7/350 2024-04-13 09:34 by haomaier
[¿¼ÑÐ] 266Çóµ÷¼Á +3 ¡«ËÖÌÇ 2024-04-12 15/750 2024-04-12 21:22 by ÕÔÑà¸ßÏÉÀ¼
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û